MURRAY HILL, N.J.--(BUSINESS WIRE)--Jan. 12, 2005--C. R. Bard,
Inc. (NYSE:BCR) today announced that it has acquired certain assets of
Genyx Medical, Inc., of Aliso Viejo, California, related to the
Uryx(R) implantable bulking agent for the treatment of stress urinary
incontinence. Bard acquired the right to purchase these assets from
Genyx in December 2002. The Uryx product has received pre-market
approval from the U.S. Food and Drug Administration and Bard
anticipates its launch in the first half of 2005. The company's
Urological division, located in Covington, Georgia, will market the
Stress urinary incontinence is an often debilitating condition
that affects an estimated 50 million people globally, 85 percent of
whom are women. Minimally invasive bulking agent therapy can be a
first line treatment choice and is often used for patients who are not
candidates for surgery. The Uryx product is a proprietary polymer
implanted into the tissue surrounding the urethra to reduce or
eliminate this form of urinary incontinence.
Timothy M. Ring, chairman and chief executive officer, commented,
"With the aging population and the increasing demand for more
effective, minimally-invasive therapies for stress urinary
incontinence, we view this acquisition as an important opportunity for
Bard. We believe that the addition of the Uryx device will further
strengthen our broad product line and enhance our position in the
C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill,
N.J., is a leading multinational developer, manufacturer, and marketer
of innovative, life-enhancing medical technologies in the fields of
vascular, urology, oncology and surgical specialty products.
This press release may contain forward-looking statements, the
accuracy of which is necessarily subject to risks and uncertainties.
Please refer to our September 30, 2004 10-Q for a statement with
regard to forward-looking statements, including disclosure of the
factors that could cause actual results to differ materially from
those expressed or implied.
CONTACT: C. R. Bard, Inc.
Eric J. Shick, 908-277-8413
Holly P. Glass, 703-754-2848
SOURCE: C. R. Bard, Inc.